证券代码： 600566 证券简称： 济川药业 公告编号： 2025-074 湖北济川药业股份有限公司 第十届监事会第十六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 （一）本次会议的召开符合《公司法》《公司章程》《监事会议事规则》的 规定。 （二）本次会议通知和相关资料于2025年9月4日以书面方式送达全体监事。 （三）本次会议于2025年9月9日在湖北济川药业股份有限公司（以下简称"公 司"）办公大楼十楼会议室以现场表决的方式召开。 （四）本次会议由监事会主席周新春召集并主持。 （五）本次会议应参会监事3人，实际参会监事3人。 二、监事会会议审议情况 （一）审议通过《关于 2022 年限制性股票与股票期权激励计划首次授予部 分第一个解除限售期解除限售条件及第一个行权期行权条件成就的议案》 公司《激励计划》首次授予部分第一个解除限售期解除限售条件及第一个行 权期行权条件均已成就，可按相关比例进行解除限售和行权,同意公司为符合条 件的58名激励对象办理首次授予限制性股票第一个限售期解除 ...

湖北济川药业股份有限公司董事会薪酬与考核委员会 关于 2022 年限制性股票与股票期权激励计划 相关事项的核查意见 湖北济川药业股份有限公司（以下简称"公司"）董事会薪酬与考核委员会 根据《上市公司股权激励管理办法》等法律、法规及规范性文件和《公司章程》 的规定，对公司 2022 年限制性股票与股票期权激励计划相关事项进行了核查， 发表核查意见如下： 一、关于 2022 年限制性股票与股票期权激励计划首次授予部分第一个解除 限售期解除限售条件及第一个行权期行权条件成就的核查意见 公司董事会薪酬与考核委员会对 2022 年限制性股票与股票期权激励计划首 次授予部分第一个解除限售期解除限售条件及第一个行权期行权条件成就情况 及激励对象名单进行了核查，本次符合限制性股票解除限售条件的激励对象为 58 名，拟解除限售股份数量为 1,630,800 股；本次符合行权条件的股票期权激 励对象为 60 名，拟行权股份数量为 1,714,800 份。本次可行权及解除限售激励 对象资格符合《上市公司股权激励管理办法》及《激励计划》等有关规定，可行 权及解除限售的激励对象的资格合法、有效。 二、关于调整 2022 年限制性股票与 ...

证券代码： 600566 证券简称： 济川药业 公告编号： 2025-073 湖北济川药业股份有限公司 第十届董事会第十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 （一）本次会议的召开符合《公司法》《公司章程》《董事会议事规则》的 规定。 （二）本次会议通知和相关资料于 2025 年 9 月 4 日以电话和电子邮件的方 式送达全体董事和监事。 （三）本次会议于 2025 年 9 月 9 日在湖北济川药业股份有限公司（以下简 称"公司"）办公大楼十楼会议室以现场及通讯表决的方式召开。 （四）本次会议应参加董事 7 人，实际参加董事 7 人，其中独立董事姚宏先 生、卢超军先生、杨玉海先生以通讯方式出席会议。 （五）本次会议由董事长曹龙祥先生召集和主持，公司全体监事及高级管理 人员列席会议。 表决结果：同意 4 票，反对 0 票，弃权 0 票。本议案获得通过。 曹龙祥先生、黄曲荣先生、曹伟先生为本议案的关联董事，已回避表决。 该议案已经董事会薪酬与考核委员会审议通过。 （二）审议通过《关 ...

证券代码： 600566 证券简称： 济川药业 公告编号： 2025-072 湖北济川药业股份有限公司 关于全资子公司利用闲置募集资金 进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 （一）现金管理目的 鉴于目前公司募集资金投资项目的实际情况，预计在未来一定时间内，公司 仍有部分暂时闲置的募集资金。为充分提高募集资金使用效率，根据《上市公司 监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上海证券交易 所上市公司自律监管指引第 1 号——规范运作》和《湖北济川药业股份有限公司 募集资金管理制度》的相关规定，在不影响募投项目建设正常进行的前提下，公 司拟使用人民币 10,000 万元的闲置募集资金进行现金管理。 （二）资金来源 1、资金来源：10,000 万元的 2020 年非公开发行股票闲置募集资金。 1 委托现金管理受托方：杭州银行股份有限公司上海分行（以下简称"杭 州银行") 本次现金管理金额：人民币 10,000 万元 本次现金管理产品名称及本次现金管理期限： (一) 杭州银行"添利 ...

Core Viewpoint - On September 8, a total of 21 listed companies had their restricted shares unlocked, with a total market value of approximately 35.072 billion yuan [1] Summary by Category Restricted Share Unlocking - The specific situation of restricted share unlocking includes various companies and the types of shares being unlocked, such as equity incentive restricted circulation and pre-issue share restrictions [1] - Notable companies include: - Xizang Mining (000762) with 17,300 shares unlocked - Fida Environmental Protection (600526) with 9.284 million shares unlocked - Jichuan Pharmaceutical (600566) with 2.073 million shares unlocked - Nanguang Energy Storage (600995) with 2.234 billion shares unlocked, the largest among the listed companies [1] Market Impact - The total market value of the unlocked shares is significant, indicating potential liquidity changes in the market [1] - Companies like Xibu Gold (601069) and Shengtong Energy (001331) also had substantial amounts of shares unlocked, with 198 million and 126 million shares respectively [1]

Core Viewpoint - The company is utilizing idle raised funds for cash management, with a total amount not exceeding 580 million RMB, ensuring the safety and liquidity of investments while maintaining the normal implementation of fundraising projects [2][9]. Summary by Sections Previous Cash Management - The company previously redeemed cash management products, recovering a total principal of 112 million RMB with respective earnings of 129,100 RMB, 292,600 RMB, and 616,400 RMB, and annualized returns of 2.17%, 1.20%, and 2.50% [4][3]. Current Cash Management Overview - The purpose of cash management is to enhance the efficiency of idle raised funds, with a current cash management amount of 20 million RMB [5][6]. - The source of funds for this cash management is from idle raised funds from a non-public offering in 2020 [7][8]. Cash Management Details - The company plans to invest 10 million RMB each in two structured deposits at Bohai Bank [9]. Approval Process - The cash management proposal was approved during the board and supervisory meetings held on April 25, 2025, and the annual shareholders' meeting on May 16, 2025 [9]. Financial Impact - As of June 30, 2025, the company's debt-to-asset ratio was 18.85%, indicating no significant debt while engaging in cash management [11]. - The cash management principal will be recorded as "trading financial assets" on the balance sheet, with earnings reflected in the profit statement as "investment income" [11]. Recent Cash Management Activities - The company has been actively managing raised funds over the past twelve months, indicating a strategic approach to utilizing idle resources [11].

Core Viewpoint - Hubei Jichuan Pharmaceutical Co., Ltd. is utilizing idle raised funds for cash management, specifically investing RMB 20 million in structured deposits with Bohai Bank, aiming to enhance fund efficiency while ensuring the safety of the raised funds [1][3]. Summary by Sections Cash Management Overview - The cash management involves an investment of RMB 20 million in two structured deposit products from Bohai Bank, each with a term of 181 days [1]. - The company has previously approved the use of up to RMB 580 million of idle raised funds for cash management, ensuring it does not affect the normal implementation of investment projects [1][5]. Previous Cash Management Activities - In previous cash management activities, the company redeemed a total of RMB 112 million from various cash management products, yielding returns of RMB 12.91 thousand, RMB 29.26 thousand, and RMB 61.64 thousand, with annualized returns of 2.17%, 1.20%, and 2.50% respectively [2][3]. Purpose and Compliance - The purpose of cash management is to improve the efficiency of idle raised funds while complying with regulatory requirements and ensuring that the funds are used safely and effectively [3][4]. - The company has established a three-party supervision agreement with the sponsor and the bank to ensure proper management of the raised funds [4]. Financial Impact - As of June 30, 2025, the company's asset-liability ratio stands at 18.85%, indicating a stable financial position without significant debt [6]. - The cash management principal will be recorded as "trading financial assets" on the balance sheet, with the income recognized in the profit statement as "investment income" [6][7]. Recent Cash Management Performance - In the last twelve months, the company has engaged in cash management activities with a total investment of RMB 45 million, achieving a cumulative return of 0.52% of the last year's net profit [7][8]. - The highest single-day investment in the past year was RMB 60 million, representing 4.08% of the last year's net assets [8].

Summary of Key Points Core Viewpoint - The acquisition of Hubei Jichuan Pharmaceutical Co., Ltd. by Cao Fei through Jichuan Holdings is a strategic move that complies with legal requirements, ensuring the company's continued operation and governance integrity [1][2]. Group 1: Acquisition Overview - Cao Fei acquired 10.10% of Jichuan Holdings for 10.1 million yuan, resulting in a 60% ownership stake in Jichuan Holdings, which indirectly controls 516,757,360 shares of Jichuan Pharmaceutical, representing 56.07% of the total share capital [1][2]. - The acquisition triggered a mandatory tender offer due to holding over 30% of the company's shares, aimed at fulfilling legal obligations rather than delisting the company [2]. Group 2: Tender Offer Details - The initial offer price was set at 26.93 yuan per share, later adjusted to 24.85 yuan based on the 2024 profit distribution plan, with a tender offer period from June 18, 2025, to July 17, 2025 [3]. - By the end of the tender offer period, only 34 shareholders accepted the offer, totaling 16,300 shares, which is 0.0018% of the total share capital [3]. Group 3: Post-Acquisition Shareholding Structure - After the acquisition, Cao Fei directly holds 16,300 shares and indirectly controls 516,773,660 shares, maintaining a 56.07% stake in the company [4]. - The combined control of Cao Fei and his associate Cao Longxiang amounts to 61.15% of the total share capital, ensuring compliance with listing requirements [4]. Group 4: Compliance and Governance - During the continuous supervision period, Cao Fei and associates adhered to legal and regulatory requirements, ensuring proper governance and independent operation of Jichuan Pharmaceutical [5]. - The company has improved its governance structure and information disclosure practices, aligning with regulatory standards [5]. Group 5: Commitments and Future Plans - Commitments were made to reduce and regulate related party transactions, avoid competition, and maintain the independence of the company’s operations [6][7]. - No plans were disclosed for significant changes to the company's main business, asset sales, mergers, management adjustments, or amendments to the company’s articles of association within the next 12 months [8][9][10]. Group 6: Financial Integrity - There were no violations regarding the provision of guarantees or loans to the acquirer or related parties that could harm the interests of Jichuan Pharmaceutical [11]. - The financial advisor confirmed that all actions taken during the supervision period were compliant with regulations and did not violate any commitments [11].

北京博星证券投资顾问有限公司 关于曹飞 要约收购湖北济川药业股份有限公司 之 二〇二五年九月 北京博星证券投资顾问有限公司（以下简称"本财务顾问""博星证券"） 接受收购人曹飞的委托，担任曹飞要约收购湖北济川药业股份有限公司（以下简 称"上市公司""公司"或"济川药业"）的财务顾问。博星证券作为本次要约 收购的收购方财务顾问，持续督导期为济川药业公告要约收购报告书之日起至要 约收购完成后的 12 个月止（即 2025 年 6 月 16 日至 2026 年 8 月 1 日）。2025 年 8 月 23 日，济川药业披露了《2025 年半年度报告》。根据《中华人民共和国 证券法》和《上市公司收购管理办法》等法律法规和规则，本财务顾问就本次持 续督导期间内（即自 2025 年 6 月 16 日至 2025 年 6 月 30 日，以下简称"本持续 督导期"）规范运作、信息披露、履行公开承诺、落实后续计划等情况报告如下： 一、关于本次要约收购情况概述 2025 年 6 月 11 日，曹龙祥与曹飞签署《股权转让协议》，曹龙祥将其持有 的江苏济川控股集团有限公司（以下简称"济川控股"）10.10%股权以 1,010 万 元 ...

证券代码： 600566 证券简称： 济川药业 公告编号： 2025-071 湖北济川药业股份有限公司 关于全资子公司利用闲置募集资金进行现金管理 到期赎回并继续进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 委托现金管理受托方：渤海银行股份有限公司泰州分行(以下简称"渤海 银行泰州分行") 履行的审议程序：湖北济川药业股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开第十届董事会第十四次会议和第十届监事会第十四次会议， 于 2025 年 5 月 16 日召开 2024 年年度股东大会，审议通过了《关于全资子公司 利用闲置募集资金和自有资金进行现金管理的议案》，同意公司在不影响募投项 目正常实施并保证募集资金安全的前提下，使用额度不超过 5.8 亿元（含本数） 的闲置募集资金进行现金管理，投资对象为安全性高、流动性好、有保本约定、 投资期限不超过 12 个月的投资产品，包括但不限于理财产品、结构性存款、定 期存款、大额存单等。具体内容详见公司分别于 2025 年 4 ...